Headline
Pharmaceutical Contract Sales Organizations Market
Pharmaceutical Contract Sales Organizations Market was valued at US$ 8,212.02 Million in 2022 and is expected to reach to US$ 15,820.86 Million by 2030; it is estimated to record a CAGR of 8.6% from 2022 to 2030
Fish Vaccine Market
Fish Vaccine Market was valued at US$ 355.88 Million in 2022 and is expected to reach to US$ 617.38 Million by 2030; it is estimated to record a CAGR of 7.1% from 2022 to 2030
Demineralized Whey Powder Market
Demineralized Whey Powder Market was valued at US$ 709.26 Million in 2023 and is expected to reach to US$ 1,068.30 Million by 2031; it is estimated to record a CAGR of 5.3% from 2023 to 2031
Low-speed Electric Vehicles Market
Low-speed Electric Vehicles Market was valued at US$ 5,110.98 Million in 2022 and is expected to reach to US$ 8,489.94 Million by 2030; it is estimated to record a CAGR of 5.5% from 2022 to 2030
Immersion Cooling for EV Batteries Market
Immersion Cooling for EV Batteries Market was valued at US$ 1.23 Million in 2022 and is expected to reach to US$ 156.90 Million by 2030; it is estimated to record a CAGR of 91.1% from 2026 to 2030
Umbilical Cord Blood Banking Market
Umbilical Cord Blood Banking Market was valued at US$ 3,413.32 Million in 2023 and is expected to reach to US$ 7,892.17 Million by 2031; it is estimated to record a CAGR of 11.0% from 2023 to 2031
Poultry Vaccines Market
Poultry Vaccines Market was valued at US$ 2.1 Billion in 2023 and is expected to reach to US$ 4.1 Billion by 2031; it is estimated to record a CAGR of 8.6% from 2023 to 2031
Steel Wire Rope Market
Steel Wire Rope Market was valued at US$ 9.54 Billion in 2023 and is expected to reach to US$ 13.59 Billion by 2031; it is estimated to record a CAGR of 4.5% from 2023 to 2031
Playout Automation & Channel-in-a-Box Market
Playout Automation & Channel-in-a-Box Market was valued at US$ 20.6 Billion in 2023 and is expected to reach to US$ 63.3 Billion by 2031; it is estimated to record a CAGR of 15.1% from 2023 to 2031

Malaria Treatment Market was valued at US$ 3,296.98 Million in 2022 and is expected to reach to US$ 24,487.73 Million by 2030; it is estimated to record a CAGR of 28.5% from 2022 to 2030

Malaria Treatment Market

Extending Pipeline of New Drugs and Vaccines

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

A few antimalarial that are under clinical development are mentioned in the table below:

Malaria Drugs/Vaccine/Compounds Under Clinical Development

DrugDeveloperClinical Trial Stage
ArtefenomelSanofiPhase IIb
KAE609 Novartis AGPhase IIb
KAF156Novartis AGPhase IIb
DSM265Takeda Pharmaceutical CompanyPhase IIa
SANARIA PfSPZ-GA1SanariaPhase II
SANARIA PfSPZ Vaccine–Radiation Attenuated PfSPZ VaccineSanariaPhase II
SANARIA PfSPZ-CVacSanariaPhase II
MSP3-CRM-Vac4AllVac4AllPhase I
Liver-Stage Antigen-3 (LSA3)Vac4AllPhase IIa

Source: Company Website, The Insight Partners Analysis

Therefore, the growing number of antimalarial drugs/vaccines that are under clinical development are expected to boost the market growth in the coming years.

The Middle East & Africa holds the largest share of the malaria treatment market, with Nigeria, Ghana, Uganda, Angola, and Cameroon being the major contributors to the market growth in this region. However, Asia Pacific is anticipated to register the highest CAGR during the forecast period. The growth of the malaria treatment market is driven by the collaborations between the companies, growing incidences of cancer, and increasing clinical trials. Moreover, India reported an 83.34% reduction in malaria morbidity and a 92% decrease in associated mortality from 2000 to 2019. The Centers for Disease Control and Prevention (CDC) claims that pregnant women are three times more susceptible to malaria infections as compared to others. Thus, rapid diagnosis and subsequent treatment plans are essential, which favor the growth of the malaria treatment market in India. There is also an escalating demand for the RDTs as they facilitate easy and rapid diagnoses. Many international organizations and the Government of India are working towards the eradication of malaria. The introduction of the Parasight Malarial Platform for hospitals and pathology labs in India by companies such as Becton, Dickinson and Company and SightDX for the rapid diagnosis of malaria also favors the market growth. The increasing number of latent malaria cases in the country and the demand for advanced diagnostics tests are driving the growth of the malaria treatment market.

Malaria Treatment Market: Segmental Overview

Based on treatment, the global malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The vaccines segment held the largest share of the market in 2022; moreover, the same segment is anticipated to record the highest CAGR of 28.9% during the forecast period. Vaccines provide active acquired immunity against particular infectious diseases. The market for malaria vaccines is growing at a significant growth rate owing to increasing research and development activities and an increasing pipeline of vaccine candidates. Increasing research and development activities are offering lucrative opportunities for the segment growth. For instance, in March 2020, Novavax, Inc. and Serum Institute of India entered into a commercial license agreement; this will allow SII to use Novavax’s proprietary Matrix-M vaccine adjuvant with SII’s malaria vaccine candidate. Matrix-M is a key component in the malaria vaccine candidate and is currently in a Phase 2b clinical trial sponsored by the Jenner Institute, UK.

Malaria Treatment Market: Competitive Landscape and Key Developments

Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, Lupin Ltd, and Teva Pharmaceutical Industries Ltd. are among the leading companies operating in the global malaria treatment market. These players are focusing on expanding, diversifying their market presence, and acquiring a novel customer base, thereby tapping prevailing business opportunities.

  • In July 2022, the Gavi Vaccination Project, funded by the Gates Foundation, introduced the Mosquirix vaccine developed by GlaxoSmithKline (GSK) for the first time in three African countries: Kenya, Ghana, and Malawi. This vaccine was reportedly the first malaria vaccine. This was a critical first step in introducing malaria vaccines in countries with moderate to high transmission rates of malaria caused by P. falciparum.
  • In May 2021, Novartis delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries across the globe.
  • In January 2021, GSK, PATH, and Bharat Biotech (BBIL) declared that a product transfer agreement was signed for the malaria vaccine RTS,S/AS01E. The agreement included transferring the manufacturing of the RTS,S antigen portion of the vaccine and granting a license for all rights related to the malaria vaccine to BBIL. GSK retained the production of the vaccine adjuvant (AS01E) and supplied it to BBIL.
  • In May 2020, ADVANZ PHARMA Corp. Limited acquired Correvio Pharma Corp, a specialty pharmaceutical company. Under the acquisition, ADVANZ PHARMA achieved an immediate and direct commercial expansion in France, Germany, Italy, Spain, and the Benelux region.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top